---

CEO of Hummingbird Bioscience

A mathematician by training, Ingram recognized the power of bringing rational drug discovery to biologics. Intrigued by the HER3 protein, where several antibodies have shown disappointing results, Ingram co-founded Hummingbird Bioscience to fully realize the potential of emerging technologies and computational approaches for precision biotherapeutics. Since the company’s inception in 2015, Ingram has scaled its capabilities and led the team to conceptualize and build two oncology antibody therapeutics in-house that have now reached the clinic. Recognizing the potential for ADCs with a better safety-efficacy profile, he led the team to design a HER3-ADC that was recently out-licensed to Endeavor BioMedicines. 

“There have been significant advances in most disease areas over the past decade, and particularly in oncology where several new modalities have made real progress. I think what underlies the success of bringing new disease insights together with new effective and safe therapies is the increasing richness of our understanding of the molecular basis of both diseases and mechanisms of toxicity, which allows us to design and optimize much more effectively.”